Company intelligence / Profile preview
Bio4t2
San Diego, California, United Statesbio4t2.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
Bio4t2 has initiated first-in-human phase 1 clinical trials with its lead program B4t2‑001, a CAR-T therapy targeting the BT‑001 antigen in solid tumors. The trial evaluates safety, tolerability, pharmacokinetics/dynamics, and preliminary efficacy. Early results from pilot studies have enabled advancement to repeat dosing regimens without lymphodepletion using proprietary engraftment technology.
- Therapeutic areas
- Oncology
- Modalities
- CAR-T (Chimeric Antigen Receptor T cell therapy)Genetically modified autologous T cells
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on Bio4t2.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bio4t2.